Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Efficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials.
Marcelo Pitombeira de Lacerda, Meletios A Dimopoulos, Luděk Pour, Kihyun Kim, Sergey Voloshin, Hanlon Sia, Esther González, Chang‐Ki Min, Anna Sureda, Ivan Spicka, Paweł Robak, Marek Hus, Vera Zherebtsova, Merit Hanna, Vinay Jadhav, Nicholas Pirooz, Ianire Garrobo-Calleja, Lydia Eccersley, Vânia Hungria, Meral Beksaç (2025). Efficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7548.
Article24 days agoBaseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf).
Meral Beksac, Hang Quach, Vânia Hungria, Luděk Pour, Kihyun Kım, Sergey Voloshin, Hanlon Sia, Esther González, Chang‐Ki Min, Marcelo Pitombeira de Lacerda, Anna Sureda, Ivan Špıčka, Marek Hus, Vera Zherebtsova, Margaret Polinkovsky, Sybil Varghese, Shing Yip Lee, Elisabet E. Manasanch, Paweł Robak, Meletios A Dimopoulos (2025). Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7544.
Article24 days agoCharacterization of Infections in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf)–Based Regimens From the DREAMM-7 and DREAMM-8 Trials
Paweł Robak, Vânia Hungria, Luděk Pour, Kihyun Kım, Sergey Voloshin, Hanlon Sia, Esther González García, Chang‐Ki Min, Marcelo Pitombeira de Lacerda, Anna Sureda Balarí, Ivan Špıčka, Sosana Delimpasi, Marek Hus, Vera Zherebtsova, Christopher Wård, P. Joy Ho, Roman Hájek, Sebastian Grosicki, Kristin Morris, Maureen Nichols, Benga Kazeem, Elisabet E. Manasanch, Lydia Eccersley, Meral Beksaç, Meletios A Dimopoulos (2025). Characterization of Infections in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf)–Based Regimens From the DREAMM-7 and DREAMM-8 Trials. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)03965-5.
Article24 days agoBelantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Vânia Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Wård, P. Joy Ho, Roman Hájek, Kihyun Kım, Sebastian Grosicki, Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Martínez, Anna Sureda Balarí, Irwindeep Sandhu, Claudio Cerchione, Peter Ganly, Meletios A Dimopoulos, Chengcheng Fu, Mamta Garg, Al-Ola Abdallah, Moshe E. Gatt, Albert Oriol Rocafiguera, Michèle Cavo, Robert M. Rifkin, Tomoaki Fujisaki, Michał Mielnik, Joseph Ficek, Alejandro Mantero, Nick Pirooz, Sybil Varghese, Shing Yip Lee, Astrid McKeown, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy–Ghanta, Pralay Mukhopadhyay, Jacqueline Nielsen, Joanna Opalińska, María-Victoria Mateos (2025). Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. , 26(8), DOI: https://doi.org/10.1016/s1470-2045(25)00330-4.
Article24 days agoModification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials
María‐Victoria Mateos, Suzanne Trudel, Hang Quach, Paweł Robak, Meral Beksaç, Luděk Pour, Marek Hus, Kihyun Kım, Vera Zherebtsova, Sosana Delimpasi, Tomáš Jelı́nek, Christopher Wård, P. Joy Ho, Vladimir Vorobyev, Marcelo Pitombeira de Lacerda, Gracia Martínez, Ivan Špıčka, Jakub Radocha, Michèle Cavo, Claudio Cerchione, Chengcheng Fu, Kazuhito Suzuki, Rachel Rogers, Amy Phillips-Jones, Zhaohui Wang, Hena Baig, Jodie Wilkes, Xiaoou L. Zhou, Eric Lewis, Lydia Eccersley, Neal Sule, Prani Paka, Joanna Opalinska, Pralay Mukhopadhyay, Vânia Hungria, Meletios A Dimopoulos (2025). Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. , 9(22), DOI: https://doi.org/10.1182/bloodadvances.2025016949.
Article24 days ago